Lysatpharma GmbH
Operation name
2019 FE 0152
2019 FE 0152
Operation summary
Validation of the potential for a novel, biological immunotherpeutic based on extracellular vesicles for application in human medicine using the model for multiple sclerosis and and GvHD, as well as functional analyses (acronym SANPLEX)
Validation of the potential for a novel, biological immunotherpeutic based on extracellular vesicles for application in human medicine using the model for multiple sclerosis and and GvHD, as well as functional analyses (acronym SANPLEX)
Operation start date
16.10.2020
16.10.2020
Operation end date
28.02.2023
28.02.2023
Total eligible expenditure allocated to the operation
1.336.781,25
1.336.781,25
Union co-financing rate
80 %
80 %
Operation postcode
07745
07745
Country
Deutschland
Deutschland
Name of category of intervention
064 - Research and innovation processes in SMEs (including voucher programmes, innovations in the areas of operations, design, and service, as well as social innovations)
064 - Research and innovation processes in SMEs (including voucher programmes, innovations in the areas of operations, design, and service, as well as social innovations)